Vanda Pharmaceuticals Inc. — Director's Dealing 2024

May 24, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Vanda Pharmaceuticals Inc. (VNDA)
CIK: 0001347178
Period of Report: 2024-05-22

Reporting Person: Chrousos Phaedra (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-05-22	Common Stock	A	21887	—	Acquired	64125	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2024-05-22	Stock Option (right to buy)	$5.14	A	40202	Acquired	2034-05-21	Common Stock (40202)	Direct

Footnotes

F1: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on May 22, 2025, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date.

F2: This option vests and becomes exercisable with respect to 100% of the option shares on May 22, 2025, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date.